Cargando…
Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia
SUMMARY: COVID-19 lockdowns have impacted management of chronic diseases such as osteoporosis. Adherence to the 6-monthly dosing schedule of denosumab, the parenteral anti-osteoporosis medication most often used in Singapore, was significantly reduced during the lockdown period compared to that duri...
Autores principales: | Chandran, Manju, Hao, Ying, Kwee, Ann Kerwen, Cheen, Mcvin Hua Heng, Chin, Yun Ann, Ng, Valerie Yun Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379568/ https://www.ncbi.nlm.nih.gov/pubmed/34417842 http://dx.doi.org/10.1007/s00198-021-06085-0 |
Ejemplares similares
-
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015) -
Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017) -
Harmonization of Osteoporosis Guidelines: Paving the Way for Disrupting the Status Quo in Osteoporosis Management in the Asia Pacific
por: Chandran, Manju, et al.
Publicado: (2022) -
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014) -
A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)